RISK ADAPTED THERAPY FOR ACUTE MYELOID LEUKEMIA (AML) BASED ON GENETIC DATA AND MINIMAL RESIDUAL DISEASE: RESULTS OF THE AML12 TRIAL OF THE CETLAM GROUP IN ADULTS UP TO THE AGE OF 70 YEARSJ. Sierra,A. Garrido,S. Vives, M. P. Queipo de Llano,R. Guardia,M. Diaz Beya,M. Calabuig,M. Pratcorona,M. Arnan,O. Salamero,M. Cervera,M. A. Sampol,A. Garcia,C. Pedro,J. M. Marti,J. Bargay,L. Font, J. F. Nomdedu,M. Hoyos,L. Escoda,M. Batlle, B. Merchan, I. Sanchez Ortega,M. Tormo,D. Gallardo,J. M. Ribera,J. Esteve,S. BrunetHAEMATOLOGICA（2016）引用 0|浏览12暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
